The Four Seasons Hotel
October 9 and 10, 2002

CONVERGENCE IN BIOTECH

DESCRIPTION
The revolutionary advances in genetics, materials, nanotechnology and biochemistry that will lead to overlapping and extensions of 20th century businesses into 21st century conglomerates.
DISCUSSION QUESTIONS
 • As pharmaceuticals, food, and cosmetics overlap, what new regulatory pressures
should we expect to see on the horizon?
• How do you envision your company or industry playing in the new biotech
environment?
• What products and services, as a result of the biotech convergence in the 21st
century, do you believe will improve our lives?

PANELISTS

Moderator:
Christopher Ireland, President & CEO, Cheskin

Panelists:
Adele L. Boskey, PhD, Starr Chair in Mineralized Tissue Research, The Hospital for Special Surgery & Professor of Biochemistry, Weill Medical College of Cornell University
Betsy H. Cohen, Vice President, Futurist, Nestlé Purina PetCare Company
Deborah Hurley, Senior Research Associate & Adjunct Lecturer, Public Policy
Kennedy School of Government, Harvard University
Loretta Miraglia, SVP, Corporate Product Development & Innovation,
The Estée Lauder Companies
Monica R. Nassif, President & Founder, The Caldrea Company
Janet Woodcock, MD, Director, Center for Drug Evaluation & Research, FDA

TREND PAPERS:
1. Convergence in Biotech

back to the New York '02 list of roundtables